Full Title
A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants with Relapsed and/or Refractory Multiple MyelomaPurpose
Researchers want to find the best dose of BMS-986453 to treat multiple myeloma. The people in this study have multiple myeloma that came back or keeps growing even after treatment.
BMS-986453 is a form of chimeric antigen receptor (CAR) T cell therapy, a type of cellular immunotherapy. With CAR T cell therapy, white blood cells called T cells are removed from your body. The T cells are altered in a lab to recognize proteins on your cancer cells. They are then multiplied to larger numbers and returned to your body to find and destroy cancer cells.
BMS-986453 targets proteins called BCMA and GPRC5D on myeloma cells. It is given intravenously (by vein).
Who Can Join
To join this study, there are a few conditions. You must:
- Have multiple myeloma that came back or keeps growing even after treatment.
- Have recovered from the serious side effects of previous therapies before getting BMS-986453.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information and to see if you can join this study, please call Dr. Sham Mailankody’s office at 646-608-2091.